New therapeutic avenues for treatment of fibrosis: Can we learn from other diseases?

Digestive Diseases

Volumn 32, Issue , 2014, Pages 39-49

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Environmental factors; IBD; Induction of flares; Pathogenesis

Indexed keywords

ANTIINFLAMMATORY AGENT; GROWTH FACTOR RECEPTOR; PIRFENIDONE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CHRONIC DISEASE; CROHN DISEASE; FIBROSING ALVEOLITIS; HUMAN; INFLAMMATION; INTESTINAL FIBROSIS; INTESTINE MUCOSA; LIVER FIBROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECURRENT DISEASE; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; WOUND HEALING; BIOASSAY; CLINICAL TRIAL (TOPIC); FIBROSIS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATORY BOWEL DISEASES; MEDICAL RESEARCH; PATHOLOGY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FIBROSIS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATORY BOWEL DISEASES;

EID: 84919794562     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000367825     Document Type: Article

References (110)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782.
2. Whelan G, Farmer RG, Fazio VW, Goormastic M: Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 1985; 88: 1826-1833.
3. Farmer RG, Whelan G, Fazio VW: Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-1825.
4. Andres PG, Friedman LS: Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 255-281, vii.
5. Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer A, Mottet C, Burnand B, Froehlich F; Swiss Inflammatory Bowel Disease Cohort Study G: Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. Digestion 2013; 87: 212-221.
6. Pariente B, Cosnes J, Danese S, et al: Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17: 1415-1422.
7. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Lawrance IC: Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014, Epub ahead of print.
8. Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I: Results of the 4th Scientific Workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis 2014, Epub ahead of print.
9. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA: Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14: 181-194.
10. Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB, Krag A: Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014; 40: 233-249.
11. Elpek GO: Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J Gastroenterol 2014; 20: 7260-7276.
12. Schuppan D, Kim YO: Evolving therapies for liver fibrosis. J Clin Invest 2013; 123: 1887-1901.
13. Bolanos AL, Milla CM, Lira JC, Ramirez R, Checa M, Barrera L, Garcia-Alvarez J, Carbajal V, Becerril C, Gaxiola M, Pardo A, Selman M: Role of sonic Hedgehog in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L978-L990.
14. Yang JJ, Tao H, Li J: Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives. Expert Opin Ther Targets 2014; 18: 1011-1021.
15. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7:d793-d807.
16. Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, Sarobe P, Cornet ME, Feijoo E: Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 2011; 53: 327-333.
17. de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S: Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol 2005; 145: 166-177.
18. Fu K, Corbley MJ, Sun L, et al: SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscl Thromb Vasc Biol 2008; 28: 665-671.
19. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, Lam RW, Zhang GC, Zhang H, Ye T: Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011; 55: 612-625.
20. Iekushi K, Taniyama Y, Azuma J, Sanada F, Kusunoki H, Yokoi T, Koibuchi N, Okayama K, Rakugi H, Morishita R: Hepatocyte growth factor attenuates renal fibrosis through TGF-β1 suppression by apoptosis of myofibroblasts. J Hypertens 2010; 28: 2454-2461.
21. Moreno M, Gonzalo T, Kok RJ, et al: Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010; 51: 942-952.
22. Kim MY, Baik SK, Park DH, Jang YO, Suk KT, Yea CJ, Lee IY, Kim JW, Kim HS, Kwon SO, Cho MY, Ko SB, Chang SJ, Um SH, Han KH: Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 2008; 43: 889-896.
23. Yoshiji H, Noguchi R, Fukui H: Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 215-216.
24. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y: Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900.
25. Yokoi H, Mukoyama M, Sugawara A, Mori K, Nagae T, Makino H, Suganami T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002; 282:F933-F942.
26. Wei Y, Kang XL, Wang X: The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression. Exp Biol Med (Maywood) 2014; 239: 183-192.
27. Patsenker E, Stoll M, Millonig G, Agaimy A, Wissniowski T, Schneider V, Mueller S, Brenneisen R, Seitz HK, Ocker M, Stickel F: Cannabinoid receptor type I modulates alcohol- induced liver fibrosis. Mol Med 2011; 17: 1285-1294.
28. Wasmuth HE, Trautwein C: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Hepatology 2007; 45: 543-544.
29. Rancoule C, Pradere JP, Gonzalez J, Klein J, Valet P, Bascands JL, Schanstra JP, Saulnier-Blache JS: Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 2011; 20: 657-667.
30. Tager AM, LaCamera P, Shea BS, et al: The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008; 14: 45-54.
31. Iredale JP, Thompson A, Henderson NC: Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 2013; 1832: 876-883.
32. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP: Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-2745.
33. Hemmann S, Graf J, Roderfeld M, Roeb E: Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-975.
34. Wakasaki H, Ooshima A: Synthesis of lysyl oxidase in experimental hepatic fibrosis. Biochem Biophys Res Commun 1990; 166: 1201-1204.
35. Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J: Lysyl oxidase as a potential therapeutic target. Drug News Perspect 2008; 21: 218-224.
36. Lopetuso LR, Scaldaferri F, Pizarro TT: Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 2012; 5: 18.
37. Pizarro TT, Pastorelli L, Bamias G, Garg RR, Reuter BK, Mercado JR, Chieppa M, Arseneau KO, Ley K, Cominelli F: SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis 2011; 17: 2566-2584.
38. Yamaguchi H, Suzuki K, Nagata M, et al: Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium. Med Mol Morphol 2012; 45: 140-151.
39. Ding S, Walton KL, Blue RE, McNaughton K, Magness ST, Lund PK: Mucosal healing and fibrosis after acute or chronic inflammation in wild type FVB-N mice and C57Bl6 procollagen α1(I)-promoter-GFP reporter mice. PloS One 2012; 7:e42568.
40. Suzuki K, Sun X, Nagata M, Kawase T, Yamaguchi H, Sukumaran V, Kawauchi Y, Kawachi H, Nishino T, Watanabe K, Yoneyama H, Asakura H: Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium. Pathol Int 2011; 61: 228-238.
41. Zhu MY, Lu YM, Ou YX, Zhang HZ, Chen WX: Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced chronic colitis and fibrosis in rat model. J Dig Dis 2012; 13: 421-429.
42. Wengrower D, Zanninelli G, Latella G, Necozione S, Metanes I, Israeli E, Lysy J, Pines M, Papo O, Goldin E: Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol 2012; 26: 33-39.
43. Stidham RW, Xu J, Johnson LA, Kim K, Moons DS, McKenna BJ, Rubin JM, Higgins PD: Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology 2011; 141: 819-826.e1.
44. Peterson TC, Peterson MR, Raoul JM: The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. Eur J Pharmacol 2011; 662: 47-54.
45. Koon HW, Shih D, Karagiannides I, Zhao D, Fazelbhoy Z, Hing T, Xu H, Lu B, Gerard N, Pothoulakis C: Substance p modulates colitisassociated fibrosis. Am J Pathol 2010; 177: 2300-2309.
46. Mahavadi S, Flynn RS, Grider JR, Qiao LY, Murthy KS, Hazelgrove KB, Kuemmerle JF: Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice. Inflamm Bowel Dis 2011; 17: 711-719.
47. Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M, Kalluri R: Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 2010; 285: 20202-20212.
48. Ma Y, Guan Q, Bai A, Weiss CR, Hillman CL, Ma A, Zhou G, Qing G, Peng Z: Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis 2010; 16: 1040-1050.
49. Adler J, Rahal K, Swanson SD, Schmiedlin-Ren P, Rittershaus AC, Reingold LJ, Brudi JS, Shealy D, Cai A, McKenna BJ, Zimmermann EM: Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease. Inflamm Bowel Dis 2013; 19: 683-690.
50. Adler J, Swanson SD, Schmiedlin-Ren P, Higgins PD, Golembeski CP, Polydorides AD, McKenna BJ, Hussain HK, Verrot TM, Zimmermann EM: Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology 2011; 259: 127-135.
51. Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, Moskaluk CA, Cohn SM, Cominelli F: Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003; 124: 972-982.
52. Bamias G, Okazawa A, Rivera-Nieves J, Arseneau KO, De La Rue SA, Pizarro TT, Cominelli F: Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J Immunol 2007; 178: 1809-1818.
53. Gomez-de-Antonio D, Campo-Canaveral de la Cruz JL, Gonzalez-Lois C, Santos M, Millan I, Varela de Ugarte A: Heterotopic tracheal transplantation animal model of bronchiolitis obliterans: a reproducible model. Ann Transplant 2013; 18: 661-670.
54. Atanasova S, Hirschburger M, Jonigk D, Obert M, Petri K, Evers A, Hecker A, Schmitz J, Kaufmann A, Wilhelm J, Chakraborty T, Warnecke G, Gottlieb J, Padberg W, Grau V: A relevant experimental model for human bronchiolitis obliterans syndrome. J Heart Lung Transplant 2013; 32: 1131-1139.
55. Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler E: Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 67-74.
56. Hausmann M, Rechsteiner T, Caj M, Benden C, Fried M, Boehler A, Rogler G: A new heterotopic transplant animal model of intestinal fibrosis. Inflamm Bowel Dis 2013; 19: 2302-2314.
57. Tao H, Yang JJ, Shi KH, Huang C, Zhang L, Lv XW, Li J: The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014; 63: 249-254.
58. Erzin Y, Uzun H, Karatas A, Celik AF: Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J Gastroenterol Hepatol 2008; 23:e357-e362.
59. Pazahr S, Blume I, Frei P, Chuck N, Nanz D, Rogler G, Patak M, Boss A: Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience. MAGMA 2013; 26: 291-301.
60. Wong GL: Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) 2013; 1: 19-26.
61. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL: Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268: 411-419.
62. Rockey DC: Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008; 134: 8-14.
63. Pinzani M, Vizzutti F, Arena U, Marra F: Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 95-106.
64. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974.
65. Verveer C, de Knegt RJ: Non-invasive measurement of liver fibrosis: application of the FibroScan in hepatology. Scand J Gastroenterol Suppl 2006; 243: 85-88.
66. Wells AU: Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: Making a silk purse from a sow's ear. Thorax 2013; 68: 309-310.
67. Wolters PJ, Collard HR, Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157-179.
68. Spagnolo P, Rossi G, Cavazza A: Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. Exp Rev Clin Immunol 2014; 10: 1005-1017.
69. Camelo A, Dunmore R, Sleeman MA, Clarke DL: The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol 2014; 4: 173.
70. Steele MP, Schwartz DA: Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med 2013; 64: 265-276.
71. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG, Laurent GJ, Tetley TD, Chambers RC, McAnulty RJ: Diminished prostaglandin E 2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 73-82.
72. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M: Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E 2 and to express cyclooxygenase-2. J Clin Invest 1995; 95: 1861-1868.
73. Murray LA, Zhang H, Oak SR, Coelho AL, Herath A, Flaherty KR, Lee J, Bell M, Knight DA, Martinez FJ, Sleeman MA, Herzog EL, Hogaboam CM: Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol 2014; 50: 985-994.
74. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP 3rd, Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, et al: Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J Respir Crit Care Med 1995; 151: 1965-1973.
75. Coffey E, Newman DR, Sannes PL: Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis. J Histochem Cytochem 2013; 61: 671-679.
76. Xaubet A, Serrano-Mollar A, Ancochea J: Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 2014; 15: 275-281.
77. King TE Jr, Bradford WZ, Castro-Bernardini S, et al: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
78. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW: All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189: 825-831.
79. Potts J, Yogaratnam D: Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2013; 47: 361-367.
80. Kreuter M, Kardos P, Hoffstein V: Management of idiopathic pulmonary fibrosis: selected case reports. Eur Respir Rev 2014; 23: 239-248.
81. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T: Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431-1437.
82. Richeldi L, du Bois RM, Raghu G, Azuma A, et al: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
83. Antoniu SA: Nintedanib (BIBF 1120) for IPF: a tomorrow therapy? Multidiscip Respir Med 2012; 7: 41.
84. Woodcock HV, Molyneaux PL, Maher TM: Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther 2013; 7: 503-510.
85. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B: Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349: 209-220.
86. Rafei M, Galipeau J: A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases. Crit Rev Immunol 2010; 30: 449-461.
87. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovere C: The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010; 224: 93-100.
88. Daly C, Rollins BJ: Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 2003; 10: 247-257.
89. Herfarth H, Goke M, Hellerbrand C, Muhlbauer M, Vogl D, Scholmerich J, Rogler G: Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis 2003; 18: 401-405.
90. Leeb SN, Vogl D, Falk W, Schölmerich J, Rogler G, Gelbmann CM: Regulation of migration of human colonic myofibroblasts. Growth Factors 2002; 20: 81-91.
91. Spoettl T, Hausmann M, Herlyn M, Gunckel M, Dirmeier A, Falk W, Herfarth H, Schoelmerich J, Rogler G: Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal- like differentiation of monocytes. Clin Exp Immunol 2006; 145: 190-199.
92. Fichtner-Feigl S, Fuss IJ, Young CA, Watanabe T, Geissler EK, Schlitt HJ, Kitani A, Strober W: Induction of IL-13 triggers TGFbeta1- dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007; 178: 5859-5870.
93. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W: IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology 2008; 135: 2003-2013, 2013 e1-7.
94. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA: IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004; 173: 4020-4029.
95. Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Ruhl A, Rogler G: Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut 2013; 62: 63-72.
96. Antoniou KM, Margaritopoulos GA, Siafakas NM: Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281-291.
97. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr, Idiopathic Pulmonary Fibrosis Study G: A placebo- controlled trial of interferon gamma- 1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
98. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM, Group IS: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
99. Demedts M, Behr J, Buhl R, et al: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
100. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
101. Taniguchi H, Ebina M, Kondoh Y, et al: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
102. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, Group CS: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
103. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
104. Richeldi L, Costabel U, Selman M, et al: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
105. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib-IPF Study Investigators: Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo- controlled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
106. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
107. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G: Build-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
108. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J: BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
109. Raghu G, Behr J, Brown KK, et al: Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649.
110. Raghu G, Million-Rousseau R, Morganti A, et al: Efficacy and safety of macitentan in idiopathic pulmonary fibrosis: results of a prospective, randomized, double-blind, placebo- controlled trial. Clin Trials Idiopath Pulmonary Fibrosis Sarcoidosis 2012, p A3631.